Jazz Pharmaceuticals (JAZZ)
Develops rare-disease medicines across sleep, epilepsy and oncology.
$237.17
vs last close−3.40 (−1.41%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
$6.47
Revenue estimate
$1.21B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$6.60$1.68−$8.25$8.13$6.64$6.34$5.71Pending
Estimate$5.83$4.51−$6.12$5.95$6.52$4.64$6.18$6.47
Surprise+13.2%−62.7%−34.8%+36.6%+1.8%+36.6%−7.6%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$1.09B$897.8M$1.05B$1.13B$1.20B$1.07B$1.21BPending
Estimate$985.0M$1.06B$1.05B$1.11B$1.17B$978.7M$1.11B$1.21B
Surprise+10.5%−15.7%−0.1%+1.3%+2.8%+9.2%+8.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $6.65 | — | — |
| Sep 2027 | $6.81 | — | — |
| Jun 2027 | $6.64 | — | — |
| Mar 2027 | $5.63 | — | — |
| Dec 2026 | $6.45 | — | — |
| Nov 2026 | $6.47 | — | — |
| Aug 2026 | $6.18 | $5.71 | −7.6% |
| May 2026 | $4.64 | $6.34 | +36.6% |
| Feb 2026 | $6.52 | $6.64 | +1.8% |
| Nov 2025 | $5.95 | $8.13 | +36.6% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Jul 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $6.65 | — | — | $1.35B | — | — | — |
| Sep 2027 | $6.81 | — | — | $1.32B | — | — | — |
| Jun 2027 | $6.64 | — | — | $1.29B | — | — | — |
| Mar 2027 | $5.63 | — | — | $1.13B | — | — | — |
| Dec 2026 | $6.45 | — | — | $1.23B | — | — | — |
| Nov 4, 2026 | $6.47 | — | — | $1.21B | — | — | — |
| Aug 3, 2026 | $6.18 | $5.71 | −7.6% | $1.11B | $1.21B | +8.4% | +4.0% |
| May 5, 2026 | $4.64 | $6.34 | +36.6% | $978.7M | $1.07B | +9.2% | +7.7% |
| Feb 24, 2026 | $6.52 | $6.64 | +1.8% | $1.17B | $1.20B | +2.8% | +13.2% |
| Nov 5, 2025 | $5.95 | $8.13 | +36.6% | $1.11B | $1.13B | +1.3% | −2.3% |
| Aug 5, 2025 | |||||||
| May 6, 2025 | |||||||
| Feb 25, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Jul 31, 2024 | |||||||
| May 1, 2024 | |||||||
| Feb 28, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 10, 2023 | |||||||
| Mar 1, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 3, 2022 | |||||||
| May 4, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 4, 2021 | |||||||
| Feb 23, 2021 | |||||||
| Nov 2, 2020 | |||||||
| Aug 4, 2020 | |||||||
| May 5, 2020 | |||||||
| Feb 25, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 26, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 9, 2017 | |||||||
| Feb 28, 2017 | |||||||
| Nov 8, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 10, 2016 | |||||||
| Feb 23, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 5, 2015 |